571-580 of 1,790 results

  • Elizabeth Williams

    Person

    Elizabeth (Liz) Williams is a senior policy manager with KFF’s Program on Medicaid and the Uninsured, where she focuses on analysis of state fiscal conditions, Medicaid prescription drug spending and utilization, and children’s health coverage and access. Prior to joining KFF, Liz worked in program evaluation at DC’s Children’s Law Center and conducted data analysis for the City of Philadelphia and the University of Pennsylvania’s Counseling and Psychological Services. She holds a Bachelor’s in Mathematics…

  • Declines in Uncompensated Care Costs for The Uninsured under the ACA and Implications of Recent Growth in the Uninsured Rate

    Issue Brief

    The increase in the uninsured rate in recent years, as well as loss of coverage during the pandemic, has led to attention on the consequences of being uninsured. The need for medical care to test, treat, or prevent COVID-19 has also highlighted the potential consequences of uncompensated care for uninsured people. Uncompensated care costs occur because, although people who are uninsured use less care than people with coverage, most who are uninsured have limited income…

  • Sources of Payment for Uncompensated Care for the Uninsured

    Issue Brief

    This brief estimates the level of public funding that was paid to help offset providers’ uncompensated care costs for the uninsured in 2017. To conduct the analysis, we rely on several secondary data sources including government budget appropriations and expenditure data for major public programs that provided funds to cover the cost of care for the uninsured, as well as analyses of secondary data sources completed by others.

  • What Happens to Medicaid Drug Policy if the ACA is Overturned?

    Issue Brief

    The repeal of the ACA could mean loss of Medicaid coverage for up to 15 million that were enrolled in the ACA Medicaid expansion group prior to the COVID-19 pandemic; however, repeal could also mean significant changes to Medicaid prescription drug policy with implications for state and federal spending for prescription drugs for non-expansion Medicaid enrollees.

  • New KFF Survey Finds Abortion Remains Key Issue for Voters with Democrats Holding a Sizeable Edge over Republicans; A Third of Women Say They’ll Only Vote for Someone Who Shares Their Views

    News Release

    Nine months ahead of the first presidential primary of the 2024 election season, many voters, especially women, say candidates’ views on abortion will again be a key issue, and Democrats hold a strong edge over Republicans on the issue, a new KFF Health Tracking Poll finds.Three in 10 registered voters (30%) – and a third of women voters (35%) – say they will only vote for a candidate who shares their views on abortion. This…

  • Medicare Part D Beneficiaries Who Reach the Catastrophic Coverage Limit Can Expect to Pay More Out-of-Pocket for Their Prescription Drugs Next Year

    News Release

    Medicare Part D enrollees with relatively high out-of-pocket expenses can expect see their costs rise in 2020, according to a new KFF analysis. This is mainly due to an increase in how much enrollees will pay out of pocket for their prescription drugs in the Part D benefit coverage gap phase before they qualify for catastrophic coverage. The analysis finds that out-of-pocket drug costs will increase by nearly $400 -- from $2,275 in 2019 to…

  • State Policies Expanding Access to Behavioral Health Care in Medicaid

    Issue Brief

    On KFF’s 21st annual Medicaid budget survey, all responding states reported at least one initiative to expand behavioral health care in Medicaid, including crisis service and other benefit expansions, initiatives to expand telehealth and address equity, and managed care changes.

  • Abortion Bans May Limit Access to Certain Drugs Used to Treat Women with Cancer, Autoimmune Diseases, and Ulcers

    News Release

    A new KFF analysis finds that women comprise the majority of patients who rely on certain drugs that may be restricted in response to state abortion bans. Following the Supreme Court decision to overturn Roe v. Wade, some women in abortion-banning states have reported that clinicians and pharmacists denied them access to medications like methotrexate and misoprostol that are used to manage chronic conditions but are also used for medication abortions and treatment of ectopic…